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Objectives: The relation between chest pain and coronary atherosclerosis (CA) in 
patients with inflammatory joint diseases (IJD) has not been explored previously. Our 
aim was to evaluate the associations of the presence of chest pain and the predicted 
10-year risk of cardiovascular disease (CVD) by use of several CVD risk algorithms, with 
CA verified by multidetector computed tomography (MDCT) coronary angiography.
Methods: Detailed information concerning chest pain and CVD risk factors was obtained 
in 335 patients with rheumatoid arthritis and ankylosing spondylitis. In addition, 119 of 
these patients underwent MDCT coronary angiography.
results: Thirty-one percent of the patients (104/335) reported chest pain. Only six 
patients (1.8%) had atypical angina pectoris (pricking pain at rest). In 69 patients without 
chest pain, two thirds had CA, while in those who reported chest pain (n = 50), CA was 
present in 48.0%. In a logistic regression analysis, chest pain was not associated with 
CA (dependent variable) (p = 0.43). About 30% (Nagelkerke R2) of CA was explained by 
any of the CVD risk calculators: Systematic Coronary Risk Evaluation, Framingham Risk 
Score, or Reynolds Risk Score.
conclusion: The presence of chest pain was surprisingly infrequently reported in 
patients with IJD who were referred for a CVD risk evaluation. However, when present, 
chest pain was weakly associated with CA, in contrast to the predicted CVD risk by 
several risk calculators which was highly associated with the presence of CA. These 
findings suggest that clinicians treating patients with IJD should be alert of coronary 
atherosclerotic disease also in the absence of chest pain symptoms.
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inTrODUcTiOn
Patients with inflammatory joint diseases (IJD) have an increased 
risk of cardiovascular disease (CVD) (1–3). Despite this well-
established knowledge, implementation of CVD risk evaluation 
as a part of standard care in patients with IJD is deficient (4, 
5). Chest pain is a vital symptom of coronary atherosclerotic 
disease, and its presence is addressed as a natural part of a CVD 
risk assessment. Chest pain in patients with IJD may be related 
to angina pectoris or to the rheumatic disease itself, and it can 
be clinically difficult to distinguish between the two for both the 
patient and the physician. The relation between chest pain and 
coronary disease in patients with rheumatoid arthritis (RA) and 
ankylosing spondylitis (AS) has not been explored previously.
Angina pectoris is a symptom of myocardial ischemia caused 
by coronary atherosclerosis (CA) and may be diagnosed by several 
techniques. The selective coronary angiography procedure has 
become the gold standard for diagnosis of CA. This is an invasive, 
expensive, and resource-demanding procedure. Multidetector 
computed tomography (MDCT) coronary angiography is 
another imaging technique for identifying CA (6). Although 
both methods share the risks of radiation exposure and adverse 
reactions to contrast medium, MDCT coronary angiography 
has certain advantages over selective coronary angiography in 
that it is less costly, more time efficient, and entails a lower risk 
of CVD complications due to its non-invasiveness. The clinical 
utility of MDCT coronary angiography in predicting important 
CVD outcomes has been evaluated in several studies (7–9). The 
method is suitable for detection of CA in patients with moderate 
risk of CVD (10), and due to the high negative predictive value, it 
is particularly useful for excluding coronary stenosis (11).
The aim of the present report was to characterize and compare 
the various types of chest pain in patients with RA and AS who 
were referred for a CVD risk evaluation. Furthermore, we sought 
to evaluate the associations of the presence of chest pain and 
the predicted 10-year risk of CVD by use of several CVD risk 
algorithms, with CA (verified by MDCT coronary angiography).
MaTerials anD MeThODs
Patients with RA and AS were referred from a rheumatology out-
patient clinic or from general practitioners, for CVD risk evalua-
tion at the Preventive Cardio-Rheuma Clinic at Diakonhjemmet 
Hospital, Oslo, during the period March 2009–July 2012. Details 
concerning this preventive cardio-rheuma clinic and the approach 
to identify CVD risk factors, comorbidities, and biomarkers have 
been described previously (12, 13). Referred patients received a 
CVD questionnaire by mail, including detailed questions regard-
ing chest pain. At the clinical consultation, the answers in the 
patient self-reported questionnaire were verified by a cardiologist 
(AGS). The various types of chest pain were grouped into classi-
cal and non-classical angina pectoris. Non-classical chest pain 
was defined as pricking and cutting pain during rest and only 
lasting for seconds. Classical coronary chest pain was defined as 
any of the following: tightness, squeezing, pressure, compression, 
heaviness, band around the chest, and nausea lasting for 1 min 
or more. The pain should be localized centrally and/or on the 
side(s) of thorax, radiating to throat/jaw or out in the arms/back 
and related to physical activity, as walking up hill/steps, walking 
indoors/flat, or while performing housework. In order to distin-
guish possible CA that would demand urgent invasive investiga-
tions, from stable coronary artery disease, patients were also 
asked questions to clarify the duration, frequency, persistence, 
and activity level needed to trigger the pain. Our cohort consisted 
of patients with low-intensity chest pain who were not in need of 
immediate assessment with selective coronary angiography.
Patients with RA and AS at moderate to high risk of CVD 
and/or presence of chest pain were referred to MDCT coronary 
angiography.
This is an observational report from a quality assurance register. 
Ethical approval and informed patient consent was therefore not 
required. The data collection/publication has been recommended 
and approved by the Oslo University Hospitals’ Office of Privacy 
and Data Protection (2011/7318).
MDcT coronary angiography
The MDCT coronary angiography examination was performed 
at the Oslo University Hospital, Ullevaal. Two methods were 
used: first, spiral coronary artery MDCT, where 64 detectors 
were employed. This method is advantageous when perform-
ing reconstruction of the coronary arteries in several planes, 
including a three-dimensional plane. Furthermore, images of 
the coronary arteries may be reconstructed during all stages of 
the electrocardiogram (ECG) cycle. Second, the step and shoot 
technique was used. This is an ECG-gated MDCT coronary 
angiography method to reduce movement artifacts during the 
cardiac contraction cycle. To obtain optimal image quality with 
minimal movement artifacts, the heart rate should be <60 beats/
min. Therefore, the patients were given a beta blocker 2 h before 
the procedure. The step and shoot MDCT coronary angiography 
is only performed during certain phases of the heart cycle, which 
means that the radiation exposure can be reduced by as much 
as 80% compared to spiral CT. In our center, the step and shoot 
procedure reduced radiation exposure from 9–14 to 3  mSv. 
Therefore, the step and shoot MDCT coronary angiography was 
the preferred method, but when heart rate <60 beats/min was not 
obtained, spiral MDCT coronary angiography was performed.
Iodine-based intravenous contrast medium was used in both 
MDCT methods, and all patients were asked if they had aller-
gies and, specifically, if they had experienced an allergic reaction 
against contrast medium previously. Patients with previous 
allergic reactions to contrast medium were given anti-histamines 
and/or corticosteroids before the MDCT coronary angiography 
examination. Contrast medium may affect kidney function. All 
patients with indication for MDCT coronary angiography in 
this report had normal kidney function (estimated glomerular 
filtration rate ≥60 ml/min). Diabetic patients using metformin 
were asked to abstain from this medication for 48  h after the 
contrast administration. The kidney function was evaluated after 
the procedure, and in specific cases, metformin medication was 
not restarted until the kidney function was normalized.
Coronary atherosclerosis was diagnosed by the interventional 
cardiologist/radiologist. When the quality of the MDCT coro-
nary angiography images was inadequate, or if the examination 
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revealed suspicion of a significant coronary stenosis, selective 
coronary angiography was performed. In cases of coronary steno-
sis, individual evaluation was conducted regarding interventions 
such as percutaneous coronary intervention (PCI), open-heart 
surgery with coronary artery bypass grafting (CABG), or for 
optimization of cardioprotective medical treatment.
cVD risk algorithms
The risk of future CVD was calculated by applying the follow-
ing CVD risk calculators: (1) the Systematic COronary Risk 
Evaluation (SCORE) (14), which predicts the 10-year risk of a 
fatal atherosclerotic event and includes the following risk factors: 
age, sex, smoking status, systolic blood pressure (BP), and total 
cholesterol (TC); (2) the Framingham Risk Score (FRS) (15) 
incorporating age, sex, smoking status, BP, antihypertensive 
treatment, TC, high-density lipoprotein cholesterol (HDL-c), and 
diabetes; and (3) the Reynolds Risk Score (RRS) (16, 17), which 
contains age, sex, smoking status, BP, TC, HDL-c, C-reactive 
protein (CRP), and family history of premature myocardial 
infarction. Both the FRS and the RRS calculate the risk of a fatal 
or non-fatal CVD event coming 10 years.
statistics
The data are presented as crude data, and the results are expressed 
as mean ±  SD and median and interquartile range (IQR) for 
normally and non-normally distributed characteristics, respec-
tively. The data were compared using independent samples t-test, 
non-parametric tests, and χ2-tests as appropriate. A logistic 
regression model was constructed comparing CA versus no CA 
as the dependent variable in order to assess the associations with 
both chest pain and CVD risk factors. Instead of investigating 
the correlation to the CVD risk factors separately, they were 
examined collectively by applying the aforementioned CVD risk 
calculators’ estimate of future risk of a CVD event as independent 
variables in the logistic regression models. Due to the multicol-
linearity between the CVD risk calculators, separate models were 
constructed for each of the three CVD risk algorithms. Data 
analyses were performed using IBM SPSS version 20.
resUlTs
chest Pain characteristics
Of the 335 patients with RA and AS referred to the Preventive 
Cardio-Rheuma Clinic, 104 (31.0%) patients reported chest pain 
(Figure 1), of which six patients experienced non-classical angina 
pectoris (pricking pain, occurring at rest and lasting for seconds). 
In general, there were no significant differences between RA and 
AS concerning the various types (i.e., localization and relation to 
physical activity), frequency, or duration of the chest pain epi-
sodes. The types of chest pain which varied the most between RA 
and AS patients were tightness/squeezing and heaviness, radiating 
to throat/jaw or related to light housework, but these differences 
did not reach a level of statistical significance (Figure 1).
chest Pain and coronary atherosclerosis
The characteristics of the 119 patients with RA and AS referred 
to MDCT coronary angiography is described in Table  1. 
As expected, the sex distribution was inverse in RA and AS 
(p <  0.001). Disease duration was longer in patients with AS 
compared to RA patients (p = 0.01). Furthermore, AS patients 
had more hypertension (p = 0.04) and a higher calculated risk 
of CVD by use of the SCORE algorithm (p = 0.05) compared 
to RA patients. On the other hand, RA patients experienced 
more chest pain than patients with AS (p = 0.04), whereas the 
proportion of patients with CA was comparable between the 
two diagnoses (p = 0.48). Associations between CVD risk fac-
tors and CA are presented in Table 2. Patients with CA were 
older (<0.001), more often had diabetes (p = 0.001), and had a 
higher CVD risk evaluated by SCORE, FRS, and RRS (p < 0.001 
for all) compared to those without CA. In patients without 
chest pain, two thirds had CA, while in those reporting chest 
pain, approximately half of the patients had CA (Figure  2). 
In a logistic regression analysis with CA as the dependant 
variable, including chest pain and SCORE, chest pain was not 
associated with CA (dependent variable) (p = 0.43), while the 
calculated CVD risk by SCORE was highly associated with CA 
(p <  0.001) (Figure  3). Comparable results were revealed in 
logistic regression models incorporating FRS or RRS instead 
of the SCORE algorithm, where the calculated CVD risk was 
highly associated with CA (p = 0.20 and p = 0.09, respectively), 
whereas chest pain was not (p = 0.20 and p = 0.09, respectively). 
Approximately 30% (Nagelkerke R2) of CA was explained by the 
calculated CVD risk using all the three CVD risk calculators 
(data not shown).
selective coronary angiography
Twenty-five patients (21.0%) were referred to selective coro-
nary angiography based on the results of the MDCT coronary 
angiography (Figure 4). The majority of the patients examined 
with selective coronary angiography were in need of this invasive 
method to confirm or disprove a significant coronary stenosis 
(n = 18; 72.0%). Furthermore, indication for selective coronary 
angiography was found in six patients (24.0%) due to distinct 
calcification that disrupted the MDCT coronary angiography 
images and in one patient (4.0%) who had atrial fibrillation. After 
the selective coronary angiography, approximately two thirds of 
the patients were in need of optimization of the cardioprotective 
medical treatment (n = 16; 64.0%). Indication for further invasive 
procedures was found in nine patients [PCI n = 5 (20.0%) and 
CABG n = 4 (16.0%)].
DiscUssiOn
The presence of chest pain is routinely addressed during CVD 
risk evaluation. The main finding in the present report was that 
two thirds of the IJD patients without chest pain had CA verified 
by MDCT coronary angiography, which may be explained by a 
high prevalence of silent angina pectoris. Chest pain in patients 
with RA and AS was not associated with CA, but clinicians are 
advised to ask the patients about the presence of chest pain to 
reveal those with classical angina pectoris and/or at immediate 
need of intervention. To our knowledge, the lack of relationship 
between presence of chest pain and CA in patients with IJD has 
not previously been reported.
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In the general population, silent angina pectoris has been 
reported to occur in 10–15% of patients with coronary heart dis-
ease (18). In the study by Erikssen et al., the rate of cardiac events 
was four to five times higher in persons without chest pain, but 
with documented myocardial ischemia by exercise ECG, than in 
persons with no manifest ischemic disease. The study concluded 
that documentation of myocardial ischemia in asymptomatic 
patients (no chest pain) was indicative of the presence of coronary 
artery disease and was associated with progression of CA in spite 
of the absence of angina pectoris (18). Comparable findings were 
reported by Evans and colleagues, showing that in RA patients 
with asymptomatic atherosclerosis in the carotid arteries, there 
was a 2.5-fold to fourfold increased risk of acute coronary syn-
drome compared to those without carotid artery plaques (19). 
Furthermore, Maradit-Kremers et al. reported that patients with 
RA had more silent angina pectoris and myocardial infarction 
compared to patients without RA (20).
In addition to visualization of CA, coronary artery calcium 
(CAC) score may be analyzed during the MDCT coronary 
angiography procedure. The value of CAC score in predic-
tion of CVD events has been thoroughly investigated (21, 22). 
Nevertheless, neither the European Society of Cardiology/
European Atherosclerotic Society nor the American College 
of Cardiology/American Heart Association CVD prevention 
FigUre 1 | Various types of chest pain in patients with rheumatoid arthritis (ra) and ankylosing spondylitis (as).
TaBle 2 | coronary atherosclerosis in relation to cardiovascular risk 
factors and chest pain in patients with ra and as.
coronary atherosclerosis p-value
no Yes
Total patient number, n (%) 42 (35.3) 77 (64.7) –
RA, n (%) 32 (76.2) 54 (70.1) 0.48
AS, n (%) 10 (23.8) 23 (29.9) 0.48
Age, mean ± SD 53.8 ± 7.1 64.1 ± 8.0 <0.001
Sex (male/female), n (%) 11/31 (26.2/73.8) 32/45 (41.6/58.4) 0.10
Familial CVD disease, n (%) 7 (16.7) 12 (15.6) 0.88
CRP, mean ± SD 1.07 ± 1.20 1.18 ± 1.17 0.63
Diabetes, n (%) 0 (0.0) 11 (14.3) 0.01
cVD risk calculators, mean ± sD
Score 2.38 ± 2.58 5.91 ± 4.02 <0.001
Framingham Risk Score 9.92 ± 8.56 21.12 ± 13.03 <0.001
Reynolds Risk Score 4.29 ± 5.44 11.04 ± 8.55 <0.001
chesT Pain
Types of chest pain, n (%)
Tightness, squeezing 9 (21.4) 17 (22.1) 0.94
Pricking 13 (31.0) 11 (14.3) 0.03
Pressure 6 (14.3) 13 (16.9) 0.71
Compression 7 (16.7) 11 (14.3) 0.73
Heaviness 4 (9.5) 7 (9.1) 0.94
Cutting 1 (2.4) 1 (1.3) 0.66
Band around the chest 6 (14.3) 5 (6.5) 0.16
Nauseous 7 (16.7) 9 (11.7) 0.45
location, n (%)
Centrally 13 (31.0) 19 (24.7) 0.46
On the side(s) 14 (33.3) 15 (19.5) 0.09
To throat and/or jaw 2 (4.8) 8 (10.4) 0.29
Out in the arm(s) 2 (4.8) 8 (10.4) 0.29
To the back 7 (16.7) 7 (9.1) 0.22
When, n (%)
Walk up steps/hill 9 (21.4) 13 (16.9) 0.54
Walk indoors/flat 2 (4.8) 2 (2.6) 0.53
Light housework 2 (4.8) 4 (5.2) 0.92
During rest 11 (26.2) 17 (22.1) 0.61
During night/when a sleep 6 (14.3) 5 (6.5) 0.16
how often, n (%)
Monthly 15 (35.7) 17 (22.1) 0.11
Weekly 6 (14.3) 6 (7.8) 0.26
Several times per week 6 (14.3) 5 (6.5) 0.16
Duration, n (%)
Seconds 7 (16.7) 7 (9.1) 0.22
Minutes 15 (35.7) 17 (22.1) 0.11
≥Half hour 7 (16.7) 4 (5.2) 0.04
chest pain total, n (%) 24 (57.1) 26 (33.8) 0.01
RA, rheumatoid arthritis; AS, ankylosing spondylitis; CVD, cardiovascular; CRP, 
C-reactive protein; SCORE, systematic coronary risk evaluation.
TaBle 1 | Baseline characteristics of patients examined by MDcT 
coronary angiography.
ra as p-value
number 86 (72.3) 33 (27.7)
Age, median (IQR) 60.0 (54.8–68.0) 59.0 (54.5–65.5) 0.56
Sex, male/female, n (%) 21/65 (21.4)/(75.6) 22/11 (66.7)/(33.3) <0.001
Disease duration, years, 
median (IQR)
16.0 (7.0–24.8) 25.0 (15.5–31.0) 0.01
cVD risk factors, 
mean ± sD
Smoke, n (%) 16 (18.6) 5 (15.2) 0.66
BMI 24.9 ± 3.6 25.0 ± 2.3 0.25
TC, mmol/L 6.13 ± 1.27 5.88 ± 0.99 0.46
HDL-c, mmol/L 1.79 ± 0.51 1.58 ± 0.47 0.06
TG, mmol/L, median (IQR) 1.13 (0.83–1.54) 1.14 (0.87–1.66) 0.66
LDL-c, mmol/L 3.71 ± 1.02 3.65 ± 0.99 0.37
Systolic BP, mmHg 139.4 ± 20.7 145.3 ± 14.7 0.17
Diastolic BP, mmHg 81.5 ± 8.7 84.6 ± 8.9 0.09
comorbidities, n (%)
HT 45 (52.3) 24 (72.7) 0.04
Diabetes 7 (8.1) 4 (12.1) 0.50
Chest pain 41 (47.7) 9 (27.3) 0.04
Coronary atherosclerosis 54 (62.8) 23 (69.7) 0.48
cVD risk calculators, 
mean ± sD
SCORE 4.21 ± 3.88 5.86 ± 3.95 0.05
Framingham 15.97 ± 13.01 20.28 ± 11.85 0.09
Reynolds 7.88 ± 8.20 10.98 ± 8.06 0.08
Biomarkers
ESR, mean ± SD 18.5 ± 14.5 16.0 ± 11.0 0.42
CRP, median (IQR) 3.0 (1.0–6.0) 2.5 (1.0–7.6) 0.80
Medication, n (%)
Prednisolone 38 (44.2) 3 (9.1) <0.001
NSAIDs 34 (39.5) 17 (51.5) 0.22
sDMARDs 48 (55.8) 7 (21.2) 0.001
bDMARDs 29 (33.7) 13 (39.4) 0.76
Statins 6 (7.0) 1 (3.0) 0.41
HT medication 21 (24.4) 8 (24.2) 0.98
RA, rheumatoid arthritis; AS, ankylosing spondylitis; CVD, cardiovascular; BMI, 
body mass index; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; 
TG, triglycerides; LDL-c, low-density lipoprotein cholesterol; BP, blood pressure; 
HT, hypertension; SCORE, systematic coronary risk evaluation; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; NSAIDs, non-steroid anti-inflammatory 
drugs; sDMARDs, synthetic disease modifying antirheumatic drugs; bDMARDs, 
biologic disease modifying antirheumatic drugs; MDCT, multidetector computed 
tomography.
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guidelines recommend including the CAC score in the evaluation 
of CVD risk (23, 24). Interestingly, recently published evidence 
concludes that statin therapy increases the CAC score (25), which 
is counterintuitive considering the well-established protective 
effect of statin treatment on future CVD events (26). Therefore, 
the focus in our study was to evaluate the association of chest 
pain with the presence of visualized atherosclerosis and not the 
CAC score. Furthermore, we did not perform functional testing 
for myocardial ischemia in our patients, due to that patients with 
IJD often are not able to perform a test including cycling or a 
treadmill. A further limitation to our report is that a negative 
MDCT coronary angiography would not preclude myocardial 
FigUre 2 | chest pain and coronary atherosclerosis in ra and as. 
Presence of coronary atherosclerosis (examined with multidetector computed 
tomography) in rheumatoid arthritis and ankylosing spondylitis patients 
(n = 119) with and without chest pain. RA, rheumatoid arthritis; AS, 
ankylosing spondylitis.
FigUre 3 | Odds ratios for coronary atherosclerosis in ra and as. Association of coronary atherosclerosis with chest pain and the calculated CVD risk by 
several risk calculators in patients with rheumatoid arthritis and ankylosing spondylitis. Statistics: the estimates are presented as odds ratios for the presence of CA. 
The odds ratios are analyzed per unit increase of CVD risk calculated by SCORE, Framingham Risk Score, and Reynolds Risk Score. RA, rheumatoid arthritis; AS, 
ankylosing spondylitis; SCORE, systematic coronary risk evaluation; CVD, cardiovascular disease.
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ischemia due to small-vessel disease or coronary vasospasms, 
both of which could cause chest pain. However, the treatment 
consequences are greater for the presence of CA in the vessels 
evaluated by MDCT coronary angiography than for small-vessel 
pathology and vasospasms (23).
There is a preponderance of females with RA, and it is well 
documented that CVD is diagnosed at later stages in females 
compared to males (27). Furthermore, females in the general 
population have been reported to have different symptoms 
from CA than males (28, 29), and this is probably also the case 
in RA patients. Unfortunately, we were not able to analyze the 
sex difference aspect in relation to chest pain and CA due to low 
numbers and corresponding lack of power.
The spondyloarthropathies, and in particular the AS disease, 
comprise inflammation of joints in thorax more commonly than in 
RA (30). We therefore assumed that AS patients would report more 
chest pain than patients with RA. Surprisingly, the results from this 
analysis showed that the opposite was true, despite the occurrence 
of CA being equally frequent in the two diseases. Part of the expla-
nation for this difference may lie in the female preponderance in 
RA. It has been demonstrated that female RA patients report pain 
to a greater extent than male RA patients (31).
When analyzing the various types of chest pain, the number of 
patients in each symptom group was low, and we were therefore 
not able to conclude on the importance of the various types of 
chest pain and their association with CA in patients with IJD.
We cannot exclude a selection bias in our cohort in that the 
referral criteria to the Preventive Cardio-Rheuma Clinic were 
diagnosed IJD, age between 25 and 85 years, and fulfillment of 
at least one of the following criteria: known CVD risk factor(s), 
symptoms/signs of a risk factor, familial premature CVD disease, 
or simply that a patient wished to undergo CVD risk evaluation. 
Interestingly, a recent study reported that 30% of RA patients with 
CVD, diabetes, or hyperlipidemia consulted primary care physi-
cians less than annually, despite frequent visits with other health 
providers, as rheumatologists (32). Thus, there is a possibility that 
a proportion of the IJD patients at high risk of CVD were not 
referred to the Preventive Cardio-Rheuma Clinic. The European 
League Against Rheumatism recommend that CVD risk assess-
ment should be considered annually for patients with IJD and 
that predicted risk of CVD by established CVD risk algorithms 
should be adapted with a 1.5 multiplication factor for RA patients 
fulfilling certain criteria (33). Whether performance of CVD risk 
MDCT coronary angiography 
Paents at moderate/high risk of CVD and/or chest pain: 
n=119
Suspect significant 
coronary stenosis 
n=18 (15.1 %)
Calcificaon of the 
coronary vessel 
wall n=6 (5.0 %)
Atrial 
fibrillaon
n=1 (0.8 %)
Need for further diagnosis:
Referred to 
selecve coronary angiography
n=25 (21.0 %)
PCI n=5 (4.2 %)
CABG n=4 (3.4 %) 
No need for 
further diagnosis:
n=94 (79.0 %)
No indicaon for 
MDCT coronary 
angiography, n=216
RA and AS paents referred to the 
Prevenve Cardio-Rheuma clinic
N=335
FigUre 4 | results of the MDcT coronary angiography. Flowchart of 
patients undergoing MDCT coronary angiography. MDCT, multidetector 
computed tomography; CA, coronary atherosclerosis; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass grafting.
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evaluation should be the responsibility of the rheumatologist or 
other health care providers such as general practitioners, special-
ists in internal medicine, or cardiologists have been discussed (4) 
and will probably depend on the health care system and economic 
priorities in each country. However, it may be argued that the 
responsibility to ensure that a CVD risk evaluation is performed 
should lie with the rheumatologist, since many patients with IJD 
are mainly in contact with the health care system in relation to 
their joint disease (32).
In conclusion, the presence of chest pain was surprisingly 
infrequently reported in patients with IJD referred for a CVD 
risk evaluation. However, when chest pain was present, it was 
weakly associated with CA, in contrast to the predicted CVD risk 
by several risk calculators, which was highly associated with the 
presence of CA. These findings suggest that clinicians treating 
patients with IJD should be alert of coronary atherosclerotic 
disease also in the absence of chest pain symptoms.
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